tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Shandong Xinhua Pharmaceutical Secures Drug Registration for Minoxidil Liniment

Story Highlights
Shandong Xinhua Pharmaceutical Secures Drug Registration for Minoxidil Liniment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.

Shandong Xinhua Pharmaceutical Company Limited announced that it has received the Drug Registration Certificate for its Minoxidil Liniment from the National Medical Products Administration. This approval allows the company to market the product, which is used for treating male pattern baldness and alopecia areata, as an over-the-counter drug, potentially enhancing its market presence and offering new opportunities for growth.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and distribution of pharmaceutical products. The company operates in the pharmaceutical industry, offering a range of products including over-the-counter drugs.

Average Trading Volume: 8,369,606

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.52B

See more data about 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1